

# PRODUCT INFORMATION




## BAY-2402234

Item No. 33259

**CAS Registry No.:** 2225819-06-5  
**Formal Name:** N-(2-chloro-6-fluorophenyl)-4-[4-ethyl-4,5-dihydro-3-(hydroxymethyl)-5-oxo-1H-1,2,4-triazol-1-yl]-5-fluoro-2-[(1S)-2,2,2-trifluoro-1-methylethoxy]-benzamide

**MF:** C<sub>21</sub>H<sub>18</sub>ClF<sub>5</sub>N<sub>4</sub>O<sub>4</sub>  
**FW:** 520.8  
**Purity:** ≥98%  
**Supplied as:** A crystalline solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

BAY-2402234 is supplied as a crystalline solid. A stock solution may be made by dissolving the BAY-2402234 in the solvent of choice, which should be purged with an inert gas. BAY-2402234 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of BAY-2402234 in ethanol is approximately 30 mg/ml and approximately 10 mg/ml in DMSO and DMF.

BAY-2402234 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BAY-2402234 should first be dissolved in ethanol and then diluted with the aqueous buffer of choice. BAY-2402234 has a solubility of approximately 0.25 mg/ml in a 1:3 solution of ethanol:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

## Description

BAY-2402234 is an inhibitor of dihydroorotate dehydrogenase (DHODH; IC<sub>50</sub> = 1.2 nM).<sup>1</sup> It induces upregulation of the cell differentiation marker CD11b in MOLM-13 and HEL acute myeloid leukemia (AML) cells (EC<sub>50</sub>s = 3.16 and 0.96 nM, respectively) and inhibits the proliferation of nine leukemia cell lines (IC<sub>50</sub>s = 0.08-8.2 nM). BAY-2402234 induces cell cycle arrest at the G<sub>2</sub>/M phase and apoptosis in TF-1 cells in a concentration-dependent manner. *In vivo*, BAY-2402234 (1.25, 2.5, and 5 mg/kg) reduces tumor volume in an MV4-11 mouse xenograft model. It also increases survival in patient-derived xenograft (PDX) mouse models of AML.

## Reference

1. Christian, S., Merz, C., Evans, L., *et al.* The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. *Leukemia* **33**(10), 2403-2415 (2019).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/14/2022

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897

[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM